{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:11:37Z","timestamp":1792725097387,"version":"4.5.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors have been developed with the aim of reinvigorating antitumor T-cell responses in the tumor microenvironment by blocking the conversion of the essential amino acid tryptophan into immunoregulatory kynurenines. The lack of efficacy demonstrated in the clinical trials prompts us to revise the \u201con-target\u201d mechanism of these molecules. By studying the turnover of IDO1 protein in human tumor cells exposed to various IDO1 catalytic inhibitors, such as epacadostat, linrodostat, and navoximod, we show here that these molecules stabilize a non-enzymatic protein conformation of IDO1, independently of their mechanism of inhibition. In the thyroid carcinoma cell line FTC-133, the stabilized and non-enzymatic IDO1 protein promotes the proliferation and migration of the tumor, resulting in an adverse pro-tumorigenic effect. These results uncover an unexpected adverse effect of IDO1 inhibitors in the tumor microenvironment that overcomes the enzymatic inhibition of IDO1, and suggest protein degradation, rather than enzymatic inhibition, as a more effective approach to target IDO1 in the tumor microenvironment.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1680896","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T06:16:09Z","timestamp":1762236969000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Adverse pro-tumorigenic effects of IDO1 catalytic inhibitors mediated by the non-enzymatic function of IDO1 in tumor cells"],"prefix":"10.3389","volume":"16","author":[{"given":"Sofia","family":"Rossini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ambrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Suvieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Pallotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Belladonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Sorcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Macchiarulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Hennes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slava","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Waldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciriana","family":"Orabona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.531491","article-title":"IDO expression in cancer: different compartment, different functionality","volume":"11","author":"Meireson","year":"2020","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000269199.16209.22","article-title":"Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes","volume":"84","author":"Belladonna","year":"2007","journal-title":"Transplantation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trim.2006.09.017","article-title":"Tryptophan catabolism generates autoimmune-preventive regulatory T cells","volume":"17","author":"Fallarino","year":"2006","journal-title":"Transpl Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J Exp Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1719190115","article-title":"Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form","volume":"115","author":"Nelp","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-030419-033635","article-title":"Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma","volume":"4","author":"Van den Eynde","year":"2020","journal-title":"Annu Rev Cancer Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.613069","article-title":"Moonlighting proteins are important players in cancer immunology","volume":"11","author":"Adamo","year":"2021","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16086","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme","volume":"289","author":"Pallotta","year":"2022","journal-title":"FEBS J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pro.70152","article-title":"Phosphorylation of ITIM motifs drives the structural transition of indoleamine 2,3-dioxygenase 1 between enzymatic and non-enzymatic states","volume":"34","author":"Hoffka","year":"2025","journal-title":"Protein Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2012.00029","article-title":"Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase","volume":"18","author":"Orabona","year":"2012","journal-title":"Mol Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12954","article-title":"Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1","volume":"21","author":"Albini","year":"2017","journal-title":"J Cell Mol Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810278105","article-title":"SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis","volume":"105","author":"Orabona","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2170095","article-title":"The signaling function of IDO1 incites the Malignant progression of mouse B16 melanoma","volume":"12","author":"Orecchini","year":"2023","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1346686","article-title":"Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells","volume":"15","author":"Rossini","year":"2024","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.10.602857","article-title":"Identification of a Monovalent Pseudo-Natural Product Degrader Class Supercharging Degradation of IDO1 by its native E3 KLHDC3","author":"Hennes","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.neuropharm.2015.10.036","article-title":"Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells","volume":"102","author":"Volpi","year":"2016","journal-title":"Neuropharmacology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1134551","article-title":"The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1","volume":"14","author":"Panfili","year":"2023","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2020.1781811","article-title":"Advances in the discovery and development of selective heme-displacing IDO1 inhibitors","volume":"15","author":"Sun","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1637","article-title":"Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR","volume":"5","author":"Litzenburger","year":"2014","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3351","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment","volume":"99","author":"Moretti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/cancers12010145","article-title":"The aryl hydrocarbon receptor is expressed in thyroid carcinoma and appears to mediate epithelial-mesenchymal-transition","volume":"12","author":"Moretti","year":"2020","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e85872","DOI":"10.7554\/eLife.85872","article-title":"A back-door insight into the modulation of Src kinase activity by the polyamine spermidine","volume":"12","author":"Rossini","year":"2023","journal-title":"Elife"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.01.005","article-title":"A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells","volume":"46","author":"Mondanelli","year":"2017","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s42004-025-01648-2","article-title":"Ligand-induced conformations and dynamic allosteric motions of IDO1 affecting the recruitment of a protein signaling partner","volume":"8","author":"Coletti","year":"2025","journal-title":"Commun Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12618","article-title":"Functions of shp2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J Cell Mol Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100941","article-title":"An adverse tumor-protective effect of IDO1 inhibition","volume":"4","author":"Kenski","year":"2023","journal-title":"Cell Rep Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300545","article-title":"IDO1 inhibition promotes activation of tumor-intrinsic STAT3 pathway and induces adverse tumor-protective effects","volume":"212","author":"Yu","year":"2024","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-3-030-47189-7_4","article-title":"SRC signaling in cancer and tumor microenvironment","volume":"1270","author":"Caner","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0383","article-title":"SHP2: A pleiotropic target at the interface of cancer and its microenvironment","volume":"13","author":"Sodir","year":"2023","journal-title":"Cancer Discov"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1038\/s41467-022-33285-x","article-title":"USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer","volume":"13","author":"Shi","year":"2022","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00771","article-title":"Identification and characterization of a novel indoleamine 2,3-dioxygenase 1 protein degrader for glioblastoma","volume":"65","author":"Bollu","year":"2022","journal-title":"J Med Chem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.02.010","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","volume":"10","author":"Hu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00026","article-title":"Rational design and optimization of a potent IDO1 proteolysis targeting chimera (PROTAC)","volume":"68","author":"Monsen","year":"2025","journal-title":"J Med Chem"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680896\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T06:16:10Z","timestamp":1762236970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680896\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1680896"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1680896","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"article-number":"1680896"}}